[1]江 旭,李 慧,刘 航,等.影响肝细胞癌切除术后早期复发及生存的危险因素分析 [J].介入放射学杂志,2018,27(03):215-222.
　JIANG Xu,LI Hui,LIU Hang,et al.The risk factors affecting early recurrence and survival after surgical resection of hepatocellular carcinoma[J].journal interventional radiology,2018,27(03):215-222.
点击复制

影响肝细胞癌切除术后早期复发及生存的危险因素分析 



()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
27
期数:
2018年03期
页码:
215-222
栏目:
肿瘤介入
出版日期:
2018-03-25

文章信息/Info

Title:
The risk factors affecting early recurrence and survival after surgical resection of hepatocellular carcinoma
作者:
江 旭;  李 慧;  刘 航;  杨继金;  刘敬禹;  施一翔;  杨朝爱;  王卫星;  陈文会
Author(s):
JIANG Xu;  LI Hui;  LIU Hang;  YANG Jijin;  LIU Jingyu;  SHI Yixiang;  YANG Chaoai;  WANG Weixing;  CHEN Wenhui
Department of Interventional Radiology， Affiliated Changhai Hospital， Second Military Medical University， Shanghai 200433， China
关键词:
【关键词】 肝细胞癌;  复发; 术后;  危险因素;  经动脉化疗栓塞术
文献标志码:
A
摘要:

【摘要】 目的 分析肝癌切除术后3个月内复发的相关危险因素，以及影响肝切除术后生存的危险因素。方法 回顾性分析2007年1月1日至2014年3月31日收治的原发性肝细胞癌切除术后3个月内行cTACE的257例患者的临床资料，根据DSA结果（部分不明确的采用碘油CT）将其分为复发组和非复发组，进行单因素分析和多因素分析，比较患者的临床、病理资料与肝癌切除术后3个月内复发的关系。随访患者的生存时间，比较患者的临床资料与术后生存的关系。结果 ①257例患者中150例（58.4%）发现肝内有活性复发病灶（复发组），107例（41.6%）未发现肿瘤的存在（非复发组）。②子灶、包膜是术后残留的独立危险因素。③肿瘤最大径、Edmondson分级、脉管癌栓是影响生存的独立危险因素。④肝癌术后3个月内复发的患者中位生存时间较无复发组明显缩短（39个月比93个月）。结论 肝癌切除术后3个月复发与卫星子灶、肿瘤包膜相关。肝癌切除术后患者的生存与肿瘤最大径、Edmondson分级、脉管癌栓有关。肝癌术后3个月内复发的患者中位生存时间较无复发组明显缩短。

参考文献/References:

［1］ Poon RT， Fan ST， Ng IO， et al. Significance of resection margin in hepatectomy for hepatocellular carcinoma： a critical reappraisal［J］. Ann Surg， 2000， 231： 544- 551.
［2］ Imamura H， Matsuyama Y， Tanaka E， et al， Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy［J］. J Hepatol， 2003， 38： 200- 207.
［3］ Yusuke Y， Hisashi I， Ryo M， et al. Optimal duration of the early and late recurrence of hepatocellular carcinoma after hepatectomy［J］. World J Gastroenterol， 2015， 21： 1207- 1215.
［4］ Zhang BH， Chen XH， Xin Y， et al. Risk factors for residual tumor after resection of hepatocellular carcinoma［J］. World J Gastroenterol， 2011， 17： 1889- 1894.
［5］ Kamiyama T， Nakanishi K， Yokoo H， et al. Analysis of the risk factors for early death due to disease recurrence or progression within 1 year after hepatectomy in patients with hepatocellular carcinoma［J］. World J Surg Oncol， 2012， 10： 107.
［6］ Portolani N， Coniglio A， Ghidoni S， et al. Early and late recurrence after liver resection for hepatocellular carcinoma： prognostic and therapeutic implications［J］. Ann Surg， 2006， 243： 229- 235.
［7］ Taniguchi K， Yamada T， Sasaki Y， et al. Genetic and epigenetic characteristics of human multiple hepatocellular carcinoma［J］. BMC Cancer， 2010， 10： 1- 8.
［8］ Morimoto O， Nagano H， Sakon M， et al. Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas［J］. J Hepatol， 2003， 39： 215- 221.
［9］ Grigioni WF， D’Errico A， Biagini G， et al. The capsule surrounding primary liver tumors： wherefrom its prognostic significance?［J］. Int J Cancer， 1990， 45： 637- 643.
［10］ Wu TH， Yu MC， Chen TC， et al. Encapsulation is a significant prognostic factor for better outcome in large hepatocellular carcinoma［J］. J Surg Oncol， 2011， 105： 85- 90.
［11］ Ng IO， Lai EC， Ng MM， et al. Tumor encapsulation in hepatocellular carcinoma. A pathologic study of 189 cases［J］. Cancer， 1992， 70： 45- 49.
［12］ Lai CS， Ng OL， Ng MT， et al. Long- term results of resection for large hepatocellular carcinoma： a multivariate analysis of clinicopathological features［J］. Hepatology， 1990， 11： 815- 818.
［13］ Tanaka T， Yamanaka N， Oriyama T， et al. Factors regulating tumor pressure in hepatocellular carcinoma and implications for tumor spread［J］. Hepatology， 1997， 26： 283- 287.
［14］ Toyoda H， Kumada T， Tada T， et al. Non- hypervascular hypointense nodules on Gd- EOB- DTPA- enhanced MRI as a predictor of outcomes for early- stage HCC［J］. Hepatol Int， 2015， 9： 84- 92.
［15］ Lu DS， Siripongsakun S， Kyong LJ， et al. Complete tumor encapsulation on magnetic resonance imaging： a potentially useful imaging biomarker for better survival in solitary large hepatocellular carcinoma［J］. Liver Transpl， 2013， 19： 283- 291.
［16］ Nakanishi M， Chuma M， Hige S， et al. Relationship between diffusion- weighted magnetic resonance imaging and histological tumor grading of hepatocellular carcinoma［J］. Ann Surg Oncol， 2012， 19： 1302- 1309.
［17］ Ueno S， Kubo F， Sakoda M， et al. Efficacy of anatomic resection vs nonanatomic resection for small nodular hepatocellular carcinoma based on gross classification［J］. J Hepatobiliary Pancreat Surg， 2008， 15： 493- 500.
［18］ Shi M， Guo RP， Lin XJ， et al. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma： a prospective randomized trial［J］. Ann Surg， 2007， 245： 36- 43.
［19］ Goumard C， Komatsu S， Brustia R， et al. Technical feasibility and safety of laparoscopic right hepatectomy for hepatocellular carcinoma following sequential TACE- PVE： a comparative study［J］. Surg Endosc， 2017， 31： 2340- 2349.
［20］ Yoo H， Kim JH， Ko GY， et al. Sequential transcatheter arterial chemoembolization and portal vein embolization versus portal vein embolization only before major hepatectomy for patients with hepatocellular carcinoma［J］. Ann Surg Oncol， 2011， 18： 1251- 1257.
［21］ Tremosini S， Reig M， de Lope CR， et al. Treatment of early hepatocellular carcinoma： towards personalized therapy［J］. Dig Liver Dis， 2010， 42（Suppl 3）： S242- S248.
［22］ Roayaie S， Blume IN， Thung SN， et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma［J］. Gastroenterology， 2009， 137： 850- 855.
［23］ Torzilli G， Belghiti J， Kokudo N， et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers： is it adherent to the EASL/AASLD recommendations?： an observational study of the HCC East- West study group［J］. Ann Surg， 2013， 257： 929- 937.
［24］ Hou YF， Wei YG， Yang JY， et al. Microvascular invasion patterns affect survival in hepatocellular carcinoma patients after second hepatectomy［J］. J Surg Res， 2015， 200： 82- 90.
［25］ Kim JM， Kwon CH， Joh JW， et al. Incidental microscopic bile duct tumor thrombi in hepatocellular carcinoma after curative hepatectomy： a matched study［J］. Medicine （Baltimore）， 2015， 94： e450.
［26］ Llovet JM， Ricci S， Mazzaferro V， et al. Sorafenib in advanced hepatocellular carcinoma［J］. N Engl J Med， 2008， 359： 378- 390.
［27］ 姚雪松， 闫 东， 曾辉英， 等. TACE联合索拉非尼治疗不能手术切除肝细胞肝癌50例［J］. 介入放射学杂志， 2013， 22： 381- 386.
［28］ Zahavi T， Lanton T， Divon MS， et al. Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation- associated liver cancer model［J］. Oncotarget， 2016， 7： 4860- 4870.
［29］ Rahbari NN， Mehrabi A， Mollberg NM， et al. Hepatocellular carcinoma： current management and perspectives for the future［J］. Ann Surg， 2011， 253： 453- 469.
［30］ 高 嵩， 朱 旭， 杨仁杰， 等. TACE联合奥沙利铂、氟尿嘧啶、亚叶酸钙肝动脉化疗治疗中晚期原发性肝癌［J］. 介入放射学杂志， 2012， 21： 377- 383.
［31］ Allard MA， Sebagh M， Ruiz A， et al. Does pathological response for hepatocellular carcinoma in patients with cirrhosis predict outcome after liver resection or transplantation?［J］. J Hepatol， 2015， 63： 83- 92.
［32］ Kaibori M， Tanigawa N， Kariya S， et al. A prospective randomized controlled trial of preoperative whole- liver chemolipiodolization for hepatocellular carcinoma［J］. Dig Dis Sci， 2012， 57： 1404- 1412.
［33］ Zhou Y， Zhang X， Wu L， et al. Meta- analysis： preoperative transcatheter arterial chemoembolization does not improve prognosis of patients with resectable hepatocellular carcinoma［J］. BMC Gastroenterol， 2013， 13： 51.
［34］ Ha TY， Hwang S， Lee YJ， et al. Absence of benefit of transcatheter arterial chemoembolization（TACE） in patients with resectable solitary hepatocellular carcinoma［J］. World J Surg， 2015， 40： 1- 11.
［35］ Sun JJ， Wang K， Zhang CZ， et al. Postoperative adjuvant transcatheter arterial chemoembolization after R0 hepatectomy improves outcomes of patients who have hepatocellular carcinoma with microvascular invasion［J］. Ann Surg Oncol， 2015， 23： 1344- 1351.
［36］ Jiang JH， Guo Z， Lu HF， et al. Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma： propensity score analysis［J］. World J Gastroenterol， 2015， 21： 4627- 4634.
［37］ Liu C， Sun L， Xu J， et al. Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma［J］. World J Surg Oncol， 2016， 14： 100.
［38］ Ueno M， Uchiyama K， Ozawa S， et al. Adjuvant chemolipiodolization reduces early recurrence derived from intrahepatic metastasis of hepatocellular carcinoma after hepatectomy［J］. Ann Surg Oncol， 2011， 18： 3624- 3631.
［39］ Hirokawa F， Hayashi M， Asakuma M， et al. Risk factors and patterns of early recurrence after curative hepatectomy for hepatocellular carcinoma［J］. Surg Oncol， 2016， 25： 24- 29.
［40］ Morise Z， Kawabe N， Tomishige H， et al. Recent advances in the surgical treatment of hepatocellular carcinoma［J］. World J Gastroenterol， 2014， 20： 14381- 14392.

相似文献/References:

[1]姚雪松,李 槐.不可手术切除的肝细胞癌的疗效评价标准——改良ＲＥＣＩＳＴ标准更可靠[J].介入放射学杂志,2012,(03):177.
　. Ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ ｃｒｉｔｅｒｉｏｎ ｏｆ ｉｎｏｐｅｒａｂｌｅ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ｍｏｄｉｆｉｅｄ ＲＥＣＩＳＴ ａｓ ａ ｍｏｒｅ ｒｅｌｉａｂｌｅ ｓｔａｎｄａｒｄ[J].journal interventional radiology,2012,(03):177.
[2]杨熙章,吴纪瑞,杨永岩,等.灌注化疗预防肝癌术后复发[J].介入放射学杂志,1999,(02):32.
[3]梁茂全,苏洪英. 肝癌化疗栓塞前后甲胎蛋白变化模式的临床意义[J].介入放射学杂志,2012,(04):333.
　.Ｔｈｅ ｔｒａｎｓｆｏｒｍａｔｉｏｎ ｐａｔｔｅｒｎ ｏｆ ｓｅｒｕｍ аｆｅｔｏｐｒｏｔｅｉｎ ａｆｔｅｒ ｔｒａｎｓｃａｔｈｅｔｅｒ ａｒｔｅｒｉａｌ ｃｈｅｍｏｅｍｂｏｌｉｚａｔｉｏｎ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａ： ｉｔｓ ｃｌｉｎｉｃａｌ ｓｉｇｎｉｆｉｃａｎｃｅ [J].journal interventional radiology,2012,(03):333.
[4]孙 磊,施海彬,刘 圣,等.肝细胞癌肝动脉门静脉分流形成的相关因素分析[J].介入放射学杂志,2012,(03):206.
　,,et al.Ｔｈｅ ｆａｃｔｏｒｓ ｒｅｌａｔｅｄ ｔｏ ｔｈｅ ｆｏｒｍａｔｉｏｎ ｏｆ ａｒｔｅｒｉｏｐｏｒｔａｌ ｓｈｕｎｔｉｎｇ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ [J].journal interventional radiology,2012,(03):206.
[5]沈海洋,刘瑞宝,刘 岩,等. 肝右叶前、后段原发性肝癌TACE后VEGF及CD34的表达水平 ；[J].介入放射学杂志,2012,(06):469.
　SHEN Hai- yang,LIU Rui- bao,LIU Yan,et al. The expression levels of vascular endothelial growth factor and CD34 in residual cancerous tissues of primary hepatocellular carcinoma located at anterior and posterior segments of right lobe liver after TACE[J].journal interventional radiology,2012,(03):469.
[6]李晓峰,钱国军,张 磊,等. 微波高功率条件下消融原发性肝癌的初步研究[J].介入放射学杂志,2011,(12):974.
　LI Xiao-feng,QIAN Guo-jun,ZHANG Lei,et al.Microwave ablation with high output power for the treatment of hepatocellular carcinoma: a preliminary study[J].journal interventional radiology,2011,(03):974.
[7]许晓泉,施海彬,刘　　　圣,等. 外伤性颈动脉海绵窦瘘球囊栓塞术后复发危险因素分析及治疗[J].介入放射学杂志,2011,(12):931.
　XU Xiao-quan,SHI Hai-bin,LIU Sheng,et al.The analysis of risk factors and the treatment of recurrent traumatic carotid cavernous fistulas previously managed with detachable balloons[J].journal interventional radiology,2011,(03):931.
[8]彭辽河,胡晓燕,李 杰,等. 18F-FDG PET/CT显像在肝细胞癌TACE术后残留或复发病灶检出中的应用价值[J].介入放射学杂志,2012,(08):636.
　PENG Liao- he,HU Xiao- yan,LI Jie,et al. Clinical application of 18F- FDG PET/CT imaging in detecting residual lesions or recurrence foci of hepatocellular carcinoma after TACE treatment[J].journal interventional radiology,2012,(03):636.
[9]顾俊鹏,顾 朋,迪力木拉提?巴吾东,等. 大咯血的介入治疗及复发的影响因素分析[J].介入放射学杂志,2012,(11):952.
　GU Jun? peng,GU Peng,DilimulatiBawudong,et al. The interventional management of massive hemoptysis and the analysis of factors influencing its recurrence[J].journal interventional radiology,2012,(03):952.
[10]陆小华,朱小庆,茅国新.肝细胞癌相关单核苷酸多态性的研究进展[J].介入放射学杂志,2013,(06):520.
　LU Xiao? hua,ZHU Xiao? qing,MAO Guo? xin.. Hepatocellular carcinoma?蛳 related single nucleotide polymorphisms： recent advances in research[J].journal interventional radiology,2013,(03):520.
[11]任 炜,杨 薇.射频消融治疗复发性肝癌疗效及预后因素分析[J].介入放射学杂志,2015,(10):923.
　REN Wei,YANG Wei.Radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma： analysis of the therapeutic results and prognostic factors[J].journal interventional radiology,2015,(03):923.
[12]周平盛,刘 晟,王 能,等.超声引导下微波消融治疗肝细胞癌术后肿瘤复发及其危险因素分析[J].介入放射学杂志,2022,31(12):1174.
　ZHOU Pingsheng,LIU Sheng,WANG Neng,et al.Analysis of tumor recurrence and its risk factors after ultrasound-guided microwave ablation for hepatocellular carcinoma[J].journal interventional radiology,2022,31(03):1174.
[13]季亚香,奚 静,刘春艳,等.基于天冬氨酸转氨酶-血小板计数比的列线图模型对肝细胞癌射频消融治疗后复发的预测价值[J].介入放射学杂志,2024,33(01):39.
　JI Yaxiang,XI Jing,LIU Chunyan,et al.The predictive value of a nomogram model based on aspartate aminotransferase-platelet ratio index for hepatocellular carcinoma recurrence after radiofrequency ablation[J].journal interventional radiology,2024,33(03):39.

备注/Memo

备注/Memo:
（收稿日期：２０１7-０7-1０）
（本文编辑：俞瑞纲）
更新日期/Last Update: 2018-03-19